M
Michael S. Denison
Researcher at University of California, Davis
Publications - 234
Citations - 20018
Michael S. Denison is an academic researcher from University of California, Davis. The author has contributed to research in topics: Aryl hydrocarbon receptor & CALUX. The author has an hindex of 60, co-authored 233 publications receiving 18280 citations. Previous affiliations of Michael S. Denison include University of California, Berkeley & University of Texas at El Paso.
Papers
More filters
Journal ArticleDOI
The 2005 World Health Organization reevaluation of human and Mammalian toxic equivalency factors for dioxins and dioxin-like compounds.
Martin van den Berg,Linda S. Birnbaum,Michael S. Denison,Mike De Vito,William H. Farland,Mark Feeley,Heidelore Fiedler,Helen Håkansson,Annika Hanberg,Laurie C. Haws,Martin Rose,Stephen Safe,Dieter Schrenk,Chiharu Tohyama,Angelika Tritscher,Jouko Tuomisto,Mats Tysklind,Nigel J. Walker,Richard E. Peterson +18 more
TL;DR: Concern was expressed about direct application of the TEF/total toxic equivalency (TEQ) approach to abiotic matrices, such as soil, sediment, etc., for direct application in human risk assessment as the present TEF scheme and TEQ methodology are primarily intended for estimating exposure and risks via oral ingestion.
Journal ArticleDOI
Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals.
Michael S. Denison,Scott R. Nagy +1 more
TL;DR: Evidence for the structural promiscuity of AhR ligand binding is described and the current state of knowledge with regards to the activation of the AhR signaling pathway by naturally occurring exogenous and endogenous ligands is discussed.
Journal ArticleDOI
Aryl Hydrocarbon Receptor Antagonists Promote the Expansion of Human Hematopoietic Stem Cells
Anthony E. Boitano,Jian Wang,Russell Romeo,Laure C. Bouchez,Albert E. Parker,Sue E. Sutton,John R. Walker,Colin A. Flaveny,Gary H. Perdew,Michael S. Denison,Peter G. Schultz,Michael P. Cooke +11 more
TL;DR: Mechanistic studies show that SR1 acts by antagonizing the aryl hydrocarbon receptor (AHR) and AHR modulation as a means to induce ex vivo HSC expansion should facilitate the clinical use of HSC therapy.
Journal ArticleDOI
Exactly The Same But Different: Promiscuity and Diversity in the Molecular Mechanisms of Action of the Aryl Hydrocarbon (Dioxin) Receptor
TL;DR: An overview of the classical and nonclassical mechanisms that can contribute to the differential sensitivity and diversity in responses observed in humans and other species following ligand-dependent activation of the AhR signal transduction pathway is provided.
Journal ArticleDOI
Aryl hydrocarbon receptor control of a disease tolerance defence pathway
Alban Bessede,Alban Bessede,Marco Gargaro,Maria Teresa Pallotta,Davide Matino,Giuseppe Servillo,Cinzia Brunacci,Silvio Bicciato,Emilia Maria Cristina Mazza,Antonio Macchiarulo,Carmine Vacca,Rossana G. Iannitti,Luciana Tissi,Claudia Volpi,Maria Laura Belladonna,Ciriana Orabona,Roberta Bianchi,Tobias V. Lanz,Michael Platten,Maria Agnese Della Fazia,Danilo Piobbico,Teresa Zelante,Hiroshi Funakoshi,Toshikazu Nakamura,David Gilot,Michael S. Denison,Gilles J. Guillemin,James B. DuHadaway,George C. Prendergast,Richard P. Metz,Michel Geffard,Louis Boon,Matteo Pirro,Alfonso Iorio,Bernard Veyret,Luigina Romani,Ursula Grohmann,Francesca Fallarino,Paolo Puccetti +38 more
TL;DR: It was found that a first exposure of mice to LPS activated the ligand-operated transcription factor aryl hydrocarbon receptor and the hepatic enzyme tryptophan 2,3-dioxygenase, which provided an activating ligand to the former, to downregulate early inflammatory gene expression, pointing to a role for AhR in contributing to host fitness.